Treatments after progression or completion of mosun-pola
Overall, 52 patients received subsequent anti-lymphoma treatment after mosun-pola. Four patients received ASCT as consolidative therapy, including two patients who achieved a complete response and received consolidative ASCT at the end of mosun-pola treatment. Seven patients received allogeneic SCT, including two patients who achieved a complete response with mosun-pola and subsequently received allogeneic SCT as consolidative therapy. Overall, 13 patients received CAR-T cell therapy, one of whom received CAR-T cell therapy while in partial response to mosun-pola. Five patients received polatuzumab vedotin–based therapy in the context of a polatuzumab vedotin–containing regimen as the next line of therapy.